Amyloidosis Treatment Market Size & Growth Forecast 2027–2036, By Segments (End-use, Treatment), Regional Demand Trends (North America, Asia Pacific, Europe), Key Country Insights (U.S., Japan, South Korea, Germany, France, Italy), and Competitive Landscape
Market Size and Growth Outlook
Amyloidosis Treatment Market size was worth USD 6.6 billion in 2026 and is expected to grow at a 7.03% CAGR between 2027 and 2036, crossing USD 13.02 billion by 2036. The industry revenue for 2027 is assessed at USD 6.99 billion.
Get more details on this report
Request Free Sample ReportAmyloidosis Treatment Market Intelligence Snapshot
Regional Market Dynamics
- North America held a 41.72% share in 2026, supported by established diagnostic pathways, broad specialist care access, and coordinated referral networks that enable earlier treatment adoption.
- Asia Pacific is projected to grow at an 8.48% CAGR as rare disease awareness improves, specialty care expands, and greater diagnosis and treatment access increase therapy adoption across the region.
Segment Momentum
- Hospitals & Clinics held a 52.33% share in 2026 due to their ability to provide coordinated diagnosis, specialist oversight, infusion-based therapies, and multidisciplinary management for complex amyloidosis care.
- Transplantation is growing fastest as specialized centers expand capabilities and pursue more intensive treatment approaches for carefully selected patients, supporting stronger long-term disease management outcomes.
Market Expansion Drivers
- FDA-approved RNA-silencing therapy reducing transthyretin production in ATTR cardiomyopathy patients.
- Oral transthyretin stabilizer improving treatment convenience and expanding ATTR-CM patient reach.
- Expansion of multidisciplinary amyloidosis care centers strengthening coordinated diagnosis and long-term management.
Leading Market Participants
- Top companies in the amyloidosis treatment market include Pfizer Inc. (United States), Johnson & Johnson (United States), Takeda Pharmaceutical Company Limited (Japan), Bristol-Myers Squibb Company (United States), Novartis AG (Switzerland), F. Hoffmann-La Roche Ltd (Switzerland), Sanofi S.A. (France), Alnylam Pharmaceuticals, Inc. (United States), Amgen Inc. (United States), GlaxoSmithKline plc (United Kingdom).
Global Market Forecast Snapshot
Market Outlook
- 2026 Market Size: USD 6.6 billion
- 2027 Estimated Market Size: USD 6.99 billion.
- Projected Market Size: USD 13.02 billion by 2036
- Growth Forecast: 7.03% CAGR (2027-2036)
Regional and Segment Outlook
- Leading Regional Market: North America
- High-Growth Regional Hub: Asia Pacific
- Core Revenue Segment: Hospitals & Clinics (End-use) | Chemotherapy (Treatment)
- Emerging Opportunity Segment: Home Care Settings (End-use) | Transplantation (Treatment)
Market Growth Drivers and Industry Trends
FDA-approved RNA-silencing therapy reducing transthyretin production in ATTR cardiomyopathy patients
The availability of an FDA-approved RNA-silencing therapy that reduces transthyretin production is strengthening treatment options for patients with ATTR cardiomyopathy and will drive the amyloidosis treatment market by addressing an important underlying mechanism of disease progression. RNA-silencing approaches can reduce the production of transthyretin before the protein contributes to further amyloid accumulation, providing a disease-targeted therapeutic strategy rather than focusing solely on symptom management. Greater availability of an approved treatment option can also support physician adoption, improve therapeutic consideration for eligible patients, and encourage broader recognition of ATTR cardiomyopathy as a condition requiring targeted long-term intervention.
Oral transthyretin stabilizer improving treatment convenience and expanding ATTR-CM patient reach
Oral treatment options that stabilize transthyretin can improve convenience for patients and healthcare providers, supporting amyloidosis treatment market growth by making long-term disease management more accessible. An orally administered stabilizer can reduce dependence on administration settings associated with certain other treatment approaches and may fit more readily into routine patient care, particularly for individuals requiring sustained therapy. Improved convenience can also support treatment adherence and facilitate consideration of therapy among patients and clinicians, while an expanding therapeutic choice allows treatment strategies to be evaluated according to disease characteristics, patient needs, tolerability, and practical requirements for ongoing management.
Expansion of multidisciplinary amyloidosis care centers strengthening coordinated diagnosis and long-term management
The expansion of specialized multidisciplinary centers is improving coordination among the medical disciplines involved in identifying and managing amyloidosis, supporting growth of the amyloidosis treatment market through more structured patient care pathways. Amyloidosis can require collaboration among specialists responsible for cardiac evaluation, diagnostic testing, imaging, pathology, and therapeutic management, making coordinated expertise particularly important for appropriate disease recognition and treatment planning. Dedicated care centers can facilitate earlier referral, more consistent diagnostic assessment, treatment monitoring, and longitudinal follow-up, while concentrated clinical expertise can improve the ability of healthcare teams to manage complex cases and evaluate patients for available therapeutic approaches.
| Growth Driver | Impact on CAGR | Regulatory Influence | Geographic Relevance | Adoption Rate | Impact Timeline |
|---|---|---|---|---|---|
| FDA-approved RNA-silencing therapy reducing transthyretin production in ATTR cardiomyopathy patients | 2.00% | High | North America, Europe | High | Near Term |
| Oral transthyretin stabilizer improving treatment convenience and expanding ATTR-CM patient reach | 1.80% | High | North America, Europe, Asia Pacific | High | Near Term |
| Expansion of multidisciplinary amyloidosis care centers strengthening coordinated diagnosis and long-term management | 1.50% | Moderate | North America, Asia Pacific | Medium | Mid Term |
Unlock insights tailored to your business with our bespoke market research solutions.
Click to get your customized report now.
Regional Demand Dynamics
North America (Largest Region)
Holding the largest share of the amyloidosis treatment market, North America accounted for 41.72% in 2026, underpinned by advanced diagnostic capabilities, specialized treatment centers, and strong access to innovative therapies. Greater awareness of rare diseases and improvements in disease identification support earlier diagnosis and treatment, while established healthcare systems facilitate long-term management of complex amyloidosis conditions. Continued clinical research and investment in precision-oriented therapeutic approaches further strengthen the region's treatment infrastructure and overall market position.
Asia Pacific (Fastest-Growing Region)
Asia Pacific represents the fastest-growing region, supported by improving healthcare infrastructure, expanding access to specialized diagnostics, and rising awareness of rare and complex disorders. Greater investment in healthcare capacity is enabling more patients to receive appropriate evaluation and disease management, while improvements in medical education are increasing recognition of amyloidosis among healthcare professionals. Expanding access to advanced therapies and growing emphasis on specialized care are expected to strengthen regional adoption.
| Parameter | North America | Asia Pacific | Europe | Latin America | MEA |
|---|---|---|---|---|---|
| Innovation Hub i Scale Nascent Developing Advanced | |||||
| Cost-Sensitive Region i Scale Low Medium High | |||||
| Regulatory Environment i Scale Restrictive Neutral Supportive | |||||
| Demand Drivers i Scale Weak Moderate Strong | |||||
| Development Stage i Scale Emerging Developing Developed | |||||
| Adoption Rate i Scale Low Medium High | |||||
| New Entrants / Startups i Scale Sparse Moderate Dense | |||||
| Macro Indicators i Scale Weak Stable Strong |
Key Country Insights
Germany 🇩🇪
Specialized Care NetworksGermany’s amyloidosis treatment market is supported by established clinical expertise and multidisciplinary approaches for complex rare diseases. Treatment priorities include improved patient pathways, specialized diagnostic capabilities, and integration of innovative therapies within hospital and specialty care settings.
France 🇫🇷
Clinical Expertise ExpansionFrance is advancing amyloidosis treatment through specialized healthcare programs and improved management of rare conditions. Providers are focusing on multidisciplinary collaboration, diagnostic refinement, and the integration of innovative therapies to enhance care pathways for affected patients.
Italy 🇮🇹
Rare Disease Care OptimizationItaly’s amyloidosis treatment market is shaped by efforts to improve specialized care delivery and patient monitoring. Healthcare systems are emphasizing coordinated treatment networks, diagnostic accuracy, and adoption of advanced therapies to address the complexities of amyloid-related diseases.
Japan 🇯🇵
Rare Disease ManagementJapan is strengthening amyloidosis treatment practices through improved awareness, specialized medical centers, and advances in diagnostic methods. Healthcare stakeholders are focusing on timely identification and personalized management strategies to address disease progression and improve long-term patient outcomes.
South Korea 🇰🇷
Precision Medicine IntegrationSouth Korea’s amyloidosis treatment market is influenced by growing interest in precision healthcare and advanced diagnostic technologies. Medical institutions are prioritizing specialized treatment protocols, improved disease recognition, and access to newer therapies for patients with rare protein-related disorders.
United States 🇺🇸
Advanced Therapy DevelopmentThe U.S. amyloidosis treatment market is shaped by continued adoption of specialized therapies, diagnostic improvements, and coordinated care approaches. Healthcare providers are emphasizing earlier disease identification and access to targeted treatments, while pharmaceutical companies continue advancing therapeutic options for different amyloidosis forms.
Segment Leadership and Growth Trends
Amyloidosis Treatment Market Share (%), by End-use, 2026
Go beyond the chart, access full insights & data tables
Request Free Sample ReportEnd-use Segment Analysis: Hospitals & Clinics (Largest Segment) vs Home Care Settings (Fastest-Growing Segment)
The hospitals & clinics segment held the largest share of the amyloidosis treatment market at 52.33% in 2026, supported by the need for specialized diagnosis, multidisciplinary treatment, and continuous clinical monitoring. Amyloidosis management often requires coordinated care involving diagnostic evaluation, disease-specific therapies, supportive treatment, and monitoring of organ involvement, making hospitals and clinics central to treatment delivery. The availability of specialized healthcare professionals, advanced diagnostic infrastructure, and access to complex therapeutic interventions further reinforces demand within institutional settings.
Home care settings are gaining momentum as treatment approaches increasingly emphasize patient convenience, continuity of care, and reduced dependence on prolonged hospital visits. Greater availability of therapies and supportive care that can be administered or monitored outside institutional environments is encouraging a gradual shift toward decentralized management. Home-based care can also improve treatment accessibility for patients requiring ongoing disease management while reducing the logistical burden associated with frequent clinical visits, supporting stronger adoption of this setting.
Treatment Segment Analysis: Chemotherapy (Largest Segment) vs Transplantation (Fastest-Growing Segment)
In the amyloidosis treatment market, chemotherapy accounted for the largest share of 28.62% in 2026, reflecting its established role in managing disease by targeting abnormal plasma cells responsible for the production of amyloid-forming proteins. Its integration into established treatment protocols, broad clinical familiarity, and applicability across relevant patient populations continue to support utilization. Chemotherapy also remains an important component of treatment strategies where suppression of underlying disease activity is required, sustaining its position within the treatment landscape.
Transplantation is emerging as a rapidly advancing treatment approach, particularly for eligible patients requiring intensive intervention and long-term disease control. Improvements in patient selection, supportive care, and treatment management are strengthening the feasibility of transplantation within specialized clinical pathways. Increasing attention to disease modification and the pursuit of more durable therapeutic outcomes is also supporting greater consideration of transplantation, particularly in settings with advanced specialist capabilities.
| Segment | Sub-Segment | Largest Segment | Fastest Growing |
|---|---|---|---|
| End-use | Hospitals & Clinics, Ambulatory Surgical Centers, Home Care Settings, Others | Hospitals & Clinics | Home Care Settings |
| Treatment | Chemotherapy, Immunosuppressive Drugs, Transplantation, Supportive Care, Surgery, Others | Chemotherapy | Transplantation |
Competitive Landscape and Market Positioning
Leading companies in the amyloidosis treatment market:
1. Pfizer Inc. (United States)
2. Johnson & Johnson (United States)
3. Takeda Pharmaceutical Company Limited (Japan)
4. Bristol-Myers Squibb Company (United States)
5. Novartis AG (Switzerland)
6. F. Hoffmann-La Roche Ltd (Switzerland)
7. Sanofi S.A. (France)
8. Alnylam Pharmaceuticals Inc. (United States)
9. Amgen Inc. (United States)
10. GlaxoSmithKline plc (United Kingdom)
The amyloidosis treatment market is evolving through targeted therapeutic innovation aimed at addressing rare and complex disease mechanisms. Continuous clinical research is enhancing treatment precision and expanding available options. Collaborative development efforts are accelerating innovation cycles and improving patient-focused therapeutic outcomes.
| Company | Market Share | Company Revenue | Revenue CAGR (%) | Product Portfolio | Geographic Presence | Innovation / R&D Focus | Strategic Developments |
|---|---|---|---|---|---|---|---|
| Pfizer Inc. (United States) | |||||||
| Johnson & Johnson (United States) | |||||||
| Takeda Pharmaceutical Company Limited (Japan) | |||||||
| Bristol-Myers Squibb Company (United States) | |||||||
| Novartis AG (Switzerland) | |||||||
| F. Hoffmann-La Roche Ltd (Switzerland) | |||||||
| Sanofi S.A. (France) | |||||||
| Alnylam Pharmaceuticals Inc. (United States) | |||||||
| Amgen Inc. (United States) | |||||||
| GlaxoSmithKline plc (United Kingdom). |
Industry Development/News
| Company Name | Date | Key Development |
|---|---|---|
| Protego Biopharma | Feb-26 | The company closed an oversubscribed $130 million Series B financing round to accelerate the development of its lead AL amyloidosis candidate, PROT-001. This capital injection facilitates the transition of the asset into pivotal clinical trials, strengthening the company’s competitive position in the pipeline for disease-modifying therapies. |
| AstraZeneca | Feb-26 | AstraZeneca and Ionis received a positive EU regulatory recommendation for Wainzua (eplontersen) for treating transthyretin amyloidosis with polyneuropathy. Based on Phase III NEURO-TTRansform trial data, the approval progress marks a critical expansion in commercial availability for this RNA-targeted therapy, aiming to address significant unmet needs in patients with hereditary disease. |
| GSK | Feb-26 | Results from the global CARES Phase III program evaluating anselamimab in AL amyloidosis showed that the therapy did not meet the primary endpoint in the overall patient population. However, observed therapeutic signals in specific patient subgroups support ongoing evaluation, representing a nuanced development in the landscape for anti-fibril treatments targeting protein misfolding disorders. |
Customize Your Report
Explore examples of how this report can be tailored to different research needs, including custom segments, additional topics or chapters, and related reports. Click a section of the wheel or its numbered marker to explore the available options.
Amyloidosis Treatment Market — Custom Segments
| Segment | Sub-Segment |
|---|---|
| Disease Type | AL Amyloidosis, ATTR Amyloidosis, AA Amyloidosis, Hereditary Amyloidosis, Other Systemic Amyloidosis |
| Route of Administration | Oral, Intravenous, Subcutaneous, Other Routes |
| Therapy Line | First-Line Therapy, Second-Line Therapy, Third-Line & Later Therapy, Maintenance Therapy |
Amyloidosis Treatment Market — Custom TOC
| Custom Chapter | Custom Details |
|---|---|
| Disease Diagnosis and Treatment Gap Assessment |
|
| Emerging Therapeutic Innovation Landscape |
|
| Patient Access and Reimbursement Strategy |
|
Need a different cut of the data?
Request Custom ResearchHow big is the amyloidosis treatment market?
How is the amyloidosis treatment industry projected to perform over the next decade?
How are disease-modifying therapies reshaping treatment adoption in the amyloidosis treatment market?
How are specialized care networks improving growth opportunities in the amyloidosis treatment market?
Why do hospitals and clinics hold the largest share of the amyloidosis treatment market?
Why is transplantation the fastest-growing treatment segment in the amyloidosis treatment market?
Why is North America the leading amyloidosis treatment market?
What is driving amyloidosis treatment market growth in Asia Pacific?
Who are the major participants shaping the amyloidosis treatment landscape?
Our Clients
"The team took the time to understand our specific business needs and delivered a report that was well aligned with our objectives. Their expertise and understanding of the industry were clearly reflected in the quality and relevance of the insights provided."
Siemens Healthcare
"Our experience in acquiring the research report has been excellent. The depth of analysis, and actionable insights provided have been extremely valuable in supporting our ongoing R&D efforts."
GC Biopharma
"The report offered a comprehensive view of the market trends. The in-depth segmentation and analysis of emerging opportunities gave us a better understanding of the market."
Medtronic
Our Research Team & Methodology
Every Fundamental Business Insights report is built by a dedicated vertical research team, validated through a structured primary-and-secondary methodology, and reviewed for accuracy before it reaches you.
Research Team Overview
Prepared by the Healthcare & Medical Devices Research Team
Delivery
Published
Demand
Available
Support
Trust & Compliance
Research Domains
10 coverage areasResearch Intelligence
| Source | Reference |
|---|---|
| World Health Organization (WHO) | www.who.int |
| U.S. Food & Drug Administration (FDA) | www.fda.gov |
| European Medicines Agency (EMA) | www.ema.europa.eu |
| Centers for Disease Control and Prevention (CDC) | www.cdc.gov |
| National Institutes of Health (NIH) | www.nih.gov |
| National Center for Biotechnology Information (NCBI) | www.ncbi.nlm.nih.gov |
| PubMed | pubmed.ncbi.nlm.nih.gov |
| ClinicalTrials.gov | clinicaltrials.gov |
| International Organization for Standardization (ISO) | www.iso.org |
| ASTM International | www.astm.org |
| Advanced Medical Technology Association (AdvaMed) | www.advamed.org |
| Medical Device Innovation Consortium (MDIC) | mdic.org |
| Biotechnology Innovation Organization (BIO) | www.bio.org |
| International Federation of Pharmaceutical Manufacturers & Associations (IFPMA) | www.ifpma.org |
| U.S. Pharmacopeia (USP) | www.usp.org |
| European Directorate for the Quality of Medicines & HealthCare (EDQM) | www.edqm.eu |
| World Organisation for Animal Health (WOAH) | www.woah.org |
| American Hospital Association (AHA) | www.aha.org |
| OECD Health | www.oecd.org/health |
| World Bank Data | data.worldbank.org |
Research Workflow & Quality Assurance
Data Collection
Verified information gathered through primary and secondary research.
Data Triangulation
Cross-validation using multiple independent data sources.
Forecast Modelling
Market estimates developed using historical trends and analytical models.
Analyst Validation
Findings reviewed by domain experts for accuracy and consistency.
Editorial & Quality Review
Final editorial, quality, and compliance checks before publication.
Final Publication
Released after successful completion of the internal review process.
Report Coverage
📊 Market Assessment
- Market Size & Forecast
- Market Segmentation
- Regional Analysis
- Growth Drivers & Challenges
- Market Dynamics
🏢 Competitive Intelligence
- Competitive Landscape
- Company Profiles
- Competitive Benchmarking
- Mergers & Acquisitions
- Market Share Analysis or Key Company Strategies
🔍 Strategic Analysis
- Value Chain Analysis
- Porter's Five Forces
- PESTLE Analysis
- Pricing Trends
- Supply-Demand Analysis
🚀 Future Outlook
- Technology Landscape
- Regulatory Landscape
- Investment & Funding Landscape
- Emerging Opportunities
- Future Market Outlook
Have a question about this report or need a custom scope?
Request Customization